Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3452W HIGH $1.60
Volume
78.28 K
Value Traded
124.72 K
Short % Float
0.58%
Days to Cover
1.0
-2.37%Week
-2.97%1 Month
-66.02%3 Month
-53.23%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
16.47 M
EPS (TTM)
-0.19
P/E Ratio
-
Ent. Value
13.36 M
Total Shares
40.06 M
Float Shares
30.84 M
Insiders
23.02%
Institutions
11.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DYAI Catalyst Timeline
Dated clinical, regulatory and corporate events for Dyadic International, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dyadic International, Inc.
117Total events
2Upcoming
20Tier-1 (high impact)
2004 to 2026Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Registered direct offering and concurrent private placement of common stock and warrants
▲Platform ValidationPreclinical
C1 platform demonstrated plasmid-to-purified-protein production in ~15 days under CEPI/FBS collaboration
◆Timing GuidancePresentation
Initial purified antigen samples expected to be delivered to Scripps Research by end of July 2026
Bundibugyo Ebolasource ↗
●Timing GuidancePresentation
Customer sampling activities for alpha-lactalbumin expected to begin in mid-2026
▲Partnership / LicenseCorporate
Dyadic and Scripps Research collaborate on hantavirus antibody and vaccine development
hantavirus (Andes virus)source ↗
◆Oral PresentationPresentation
Dyadic President and COO to present at Sidoti Virtual Investor Conference
●NDA SubmissionRegulatory Filing
Gates Foundation-supported malaria antibody program advancing toward preclinical evaluation
malariasource ↗
▲Product LaunchPost-Market
Commercial launch of animal-origin-free Recombinant DNase I (RNase-free)
▲Milestone PaymentCorporate
Dyadic earns $200,000 milestone payment from Inzymes upon completion of final development activities for non-animal bovine chymosin
▲Product LaunchPost-Market
Launch of animal-origin-free recombinant DNase I (RNase-free) as first commercialized product under expanded Fermbox Bio partnership
▲Milestone PaymentCorporate
Inzymes achieved development milestones under agreement with Dyadic
▲Product LaunchPost-Market
Commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals
▲Timing Guidancealpha-lactalbuminPresentation
Sampling for recombinant alpha-lactalbumin expected early 2026
▲Timing Guidancehuman lactoferrinPresentation
Sampling for human lactoferrin expected early 2026
▲Timing Guidancerecombinant transferrinPresentation
Initial purchase orders for recombinant transferrin expected by end of 2025
▲Timing GuidanceDNase-1Presentation
Initial purchase orders for DNase-1 expected by end of 2025
▲Product LaunchPost-Market
Commercial launch of Recombinant Human Albumin targeted for late 2025 and early 2026
▲Product LaunchPost-Market
First enzyme scale-up on track for late 2025 launch (Inzymes partnership)
▲Partnership / LicenseCorporate
Development and commercialization agreement with BRIG Bio for recombinant bovine alpha-lactalbumin
●Additional Dataalpha-lactalbuminClinical Data
Sampling for cell culture research market expected in Q4 2025
▲Product Launchrecombinant serum albuminPost-Market
Animal-free serum albumin expected to be commercially launched
▲Product Launchnon-animal dairy enzymesPost-Market
First enzyme from Inzymes collaboration expected to launch
▲PublicationPresentation
Study in Vaccine validates C1 platform for SARS-CoV-2 spike protein production
SARS-CoV-2source ↗
▲Milestone PaymentCorporate
Received $0.5 million milestone payment from Proliant for recombinant serum albumin
▲Milestone PaymentCorporate
Proliant partnership milestone achieved in Q3 2025, payment anticipated in Q4 2025
▲Milestone Paymentrecombinant serum albuminCorporate
Received $1.0M in milestone payments from Proliant to date; anticipates $500K milestone in Q3 2025
●Additional Datarecombinant transferrinClinical Data
Sampling and validation for diagnostic and research use underway in Q3 2025
▲Product LaunchEN3ZYMEPost-Market
EN3ZYME launched via Fermbox Bio partnership; initial delivery completed
▲Milestone PaymentCorporate
Received $1.5M second installment from Gates Foundation grant ($3.0M total)
▼Equity OfferingCorporate
Closed public offering of 6,052,000 shares at $0.95 per share, net proceeds ~$5.3M
▲Milestone PaymentCorporate
Received $250,000 milestone payment from Inzymes for productivity achievements
▲First Patient DosedTrial
First purchase order received in cell culture media and molecular biology reagent segments
▲Partnership / LicenseCorporate
Non-exclusive CRISPR/Cas9 license agreement with ERS Genomics
▲Product Launchrecombinant serum albuminPost-Market
Expected commercial launch of animal-free serum albumin in 2025
▲Product LaunchDNase-1Post-Market
Advancing toward commercial availability of RNase-free DNase-1
▲Milestone Paymentnon-animal dairy enzymesCorporate
Expected $250,000 milestone payment from Inzymes for productivity achievements
▲Product Launchnon-animal dairy enzymesPost-Market
Expected late 2025 launch of first enzyme under Inzymes license
●Additional Datahuman lactoferrinClinical Data
Sampling for research use expected to begin in H2 2025
Past FDA Catalysts and PDUFA Decisions
How DYAI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every DYAI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Francisco Trust under agreement dated February 28, 199610% Owner | Sell | -2,616 3,280,272 held | $1.21 | 07/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DYAI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in DYAI for Q2 2026. | ||||
DYAI Institutional Ownership Trends
DYAI Short Interest
Shares sold short, counted twice a month.
0.58%
Short % of Float
of tradable shares sold short
179.0K
Shares Sold Short
-21.2% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
209.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DYAI ranks across every disease it competes in
Competitive Position is a premium feature
See how DYAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDYAI News
-DYAI
Aug 13, 2026▼ -12.5%on this news
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
Dyadic International, Inc. has announced a registered direct offering and concurrent private placement, securing approximately $2.9 million. The offering includes the sale of 3,625,000 shares of Common Stock at $0.795 each. The funds will be utilized for general corporate purposes and working capital, with the transaction expected to close by August 14, 2026.
Read more →-DYAI
Aug 12, 2026▼ -16.2%on this news· ran to -27% by day 1shared move
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
Dyadic International reported its second-quarter financial results for 2026, showcasing advancements in product commercialization and strategic partnerships. The company highlighted successful shipments of recombinant proteins and ongoing collaborations with global health organizations. Despite a slight revenue decrease and increased net loss, Dyadic's C1 biomanufacturing platform continues to validate its commercial viability.
Read more →-DYAI
Aug 3, 2026Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026
Dyadic International, Inc. will report its Q2 2026 financial results on August 12, 2026, and host a conference call at 5:00 p.m. ET. The call will provide updates on the company's performance and future strategies. Investors can access the live event and its archive through the company's website.
Read more →-DYAI
Jul 7, 2026▲ +9.5%on this news
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
Dyadic International highlights the progress of its C1 protein production platform through various global health collaborations. The platform has demonstrated its ability to produce monoclonal antibodies and vaccine antigens efficiently and cost-effectively. Recent funding from the Gates Foundation and partnerships with CEPI and Scripps Research further validate C1's potential in addressing urgent health challenges.
Read more →-DYAI
Jun 29, 2026▲ +9.9%on this news
Dyadic Expands IP Protection and Business Development Activities in Japan
Dyadic International has received patent approval from the Japan Patent Office for its Thermothelomyces heterothallica recombinant protein expression technology. This milestone strengthens Dyadic's intellectual property portfolio and supports its expansion strategy in Japan. The company is also collaborating with Intralink to enhance business development activities in key markets.
Read more →-DYAI
Jun 15, 2026▲ +16.7%on this news
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
Dyadic International is experiencing heightened interest in its C1 biomanufacturing platform amid the ongoing Bundibugyo Ebola virus outbreak. The platform's rapid production capabilities are seen as crucial for developing vaccines and monoclonal antibodies efficiently. Dyadic is pursuing multiple collaborations to enhance its platform's application in infectious disease preparedness and commercial markets.
Read more →-DYAI
Jun 15, 2026▲ +16.7%on this newsshared move
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization
Dyadic International, Inc. highlighted the increasing interest in its C1 biomanufacturing platform, especially in response to the Bundibugyo Ebola virus outbreak. The platform aims to expedite the manufacturing of vaccines and monoclonal antibodies, which are crucial during health emergencies. Recent collaborations with organizations like Scripps Research aim to advance the development of vaccine antigens for various infectious diseases. Dyadic's C1 platform is also viewed as a versatile solution that can support multiple industries, including food and industrial markets, indicating its commercial potential.
Read more →-DYAI
May 28, 2026▼ -6.6%on this news
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
Dyadic International is collaborating with Scripps Research to develop monoclonal antibodies and vaccines targeting hantaviruses, particularly the Andes virus. This partnership aims to enhance pandemic preparedness by utilizing Dyadic's C1 platform for rapid and scalable biologic production. The collaboration builds on previous work and seeks to address challenges in manufacturing during public health emergencies.
Read more →-DYAI
May 21, 2026Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Dyadic International, Inc. will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The event includes a webcast presentation and opportunities for one-on-one meetings with investors. Dyadic focuses on producing precision-engineered, animal-free proteins and enzymes for various applications, highlighting its innovative microbial platforms.
Read more →-DYAI
May 19, 2026Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Dyadic Applied BioSolutions will present at the Sidoti Virtual Investor Conference on May 20-21, 2026. Joe Hazelton, the company's President and COO, will lead the presentation, which can be accessed live. Additionally, Dyadic will offer virtual one-on-one meetings for investors, emphasizing their commitment to engagement and transparency.
Read more →-DYAI
May 13, 2026Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
Dyadic International reported its Q1 2026 financial results, highlighting significant progress in commercializing animal-free recombinant proteins. The company has secured initial orders and launched new products, including AlbuFree™ DX. Despite a notable revenue increase of 182.3% year-over-year, Dyadic continues to face operational losses. The firm is expanding its collaborations and market presence, particularly in Europe and Asia.
Read more →-DYAI
May 13, 2026DYADIC ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT COMPANY PROGRESS
Dyadic International, Inc. reported its financial results for Q1 2026, highlighting substantial revenue growth of 182.3% from the previous year. The company received initial orders for recombinant bovine transferrin from the cultivated meat sector and launched AlbuFree DX recombinant human albumin. Additionally, Dyadic expanded its collaborations with Fermbox Bio and entered agreements to distribute its recombinant products globally. Despite these advancements, the company noted a decrease in cash reserves compared to the previous quarter.
Read more →-DYAI
Apr 29, 2026▲ +8.2%on this news
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
Dyadic International, Inc. will report its Q1 2026 financial results on May 13, 2026, and host a conference call at 5:00 p.m. ET. The call will provide updates on the company's performance and future strategies. Investors can access the call via dial-in or webcast, with a replay available afterward.
Read more →-DYAI
Mar 25, 2026Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. reported its 2025 financial results, highlighting significant corporate progress, including the commercial launch of AlbuFree™ DX and expanded collaborations with Fermbox Bio and IBT Bioservices. Despite a decrease in total revenue and an increase in net loss, the company is focused on accelerating the commercialization of animal-free proteins and enzymes. Dyadic's strategic partnerships and ongoing development projects aim to enhance its market presence across various sectors.
Read more →-DYAI
Mar 25, 2026DYADIC ANNOUNCES 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS
Dyadic International, Inc. has reported its 2025 financial results and highlighted significant achievements in its commercial and collaborative efforts. The successful launch of AlbuFree DX and expanded partnerships with Fermbox Bio, IBT Bioservices, and BRIG Bio mark key advances in Dyadic's strategy to enhance its market presence. However, the company experienced a revenue decline and a decrease in cash position, which could pose challenges moving forward. Dyadic aims to continue its focus on developing animal-free proteins and enzymes across various sectors.
Read more →-DYAI
Mar 16, 2026▲ +6.5%on this news
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
Dyadic Applied BioSolutions has announced a commercial distribution partnership with IBT Bioservices, allowing Dyadic's recombinant protein products to be marketed through IBT's established sales channels. This agreement is a strategic move to transition from R&D-driven revenue to commercial product sales, enhancing market access and supporting ongoing revenue generation. The initial offerings will include recombinant DNase I and transferrin for research applications.
Read more →-DYAI
Mar 11, 2026Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
Dyadic International, Inc. will report its financial results for the year ended December 31, 2025, and host a conference call on March 25, 2026. The call will provide updates on the company's performance and future strategies. Investors can participate by dialing in or accessing a webcast of the event.
Read more →-DYAI
Mar 4, 2026Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
Dyadic Applied BioSolutions and Fermbox Bio have launched their first product, animal-origin-free Recombinant DNase I, under an expanded collaboration. This enzyme is designed for nucleic-acid clean-up and supports applications in biopharmaceutical manufacturing. The companies plan to introduce additional recombinant proteins throughout 2026, targeting high-demand segments in biotechnology and molecular diagnostics.
Read more →-DYAI
Mar 2, 2026Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
Dyadic Applied BioSolutions and Inzymes ApS announced the planned commercialization of a non-animal dairy enzyme, recombinant bovine chymosin, in 2026. This follows the successful completion of development activities under their collaboration agreement. Dyadic received a $200,000 milestone payment and is positioned to earn royalties on future sales. The partnership aims to meet the growing demand for sustainable dairy processing solutions.
Read more →-DYAI
Feb 17, 2026Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
Dyadic Applied BioSolutions and Proliant Health & Biologicals have launched AlbuFree™ DX, a recombinant human albumin product. This launch highlights Dyadic's commitment to producing animal-free proteins for life sciences. The partnership allows Dyadic to benefit from Proliant's established distribution network. The product is aimed at meeting the growing demand for scalable and supply-secure inputs in cell culture applications.
Read more →About Dyadic International, Inc.
Headquarters1044 NORTH U.S. HIGHWAY ONE, JUPITER, FL, 33477
BIOPHARMAWATCH ELITE PLUS
Trade the next DYAI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime